A phase-II academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or nivolumab in relapsed or refractory classical Hodgkin lymphoma (cHL) - cHL-PG01

Start Date13 Jan 2020

Sponsor / Collaborator-

100 Clinical Results associated with brentuximab

100 Translational Medicine associated with brentuximab

100 Patents (Medical) associated with brentuximab

149

Literatures (Medical) associated with brentuximab

01 Jan 2025·Hematological Oncology

One‐Day Brentuximab–Bendamustine (120 mg/m2) Every 21 Days is a Feasible, Safe and Effective Treatment for Relapsed/Refractory Hodgkin Lymphoma

Article

Author: Delory, T. ; Schmidt‐Hieber, C. ; Di Blasi, R. ; Ravdan, O. ; Renaud, L. ; Laroque, M‐C. ; Madelaine‐Chambrin, I. ; Thieblemont, C. ; Moatti, H. ; Wencel, J. ; Brice, P.

ABSTRACTBrentuximab vedotin (BV)‐bendamustine (90 or 120 mg/m2 day 1 and 2) every 28 days is an effective treatment for relapsed/refractory Hodgkin lymphoma (R/R HL) but associated to high toxicity especially for elderly patients. We conducted in St Louis Hospital, Paris, between 2015 and 2021 a retrospective single‐center analysis of 44 patients with R/R HL treated with one‐day BV‐bendamustine (120 mg/m2) every 21 days. Sixteen percent of patients were ≥ 60 years old (yo). Seventy‐three percent of patients received total number of cycles without interruption nor adaptation. No patient ≥ 70 yo required treatment interruption. Dose adjustment was necessary for 18% of patients. Infusion‐related reaction (36%) occurred always at cycle 2 and was the only cause of treatment interruption. One febrile neutropenia, one non‐documented septic shock, one pyelonephritis on transplanted kidney and one COVID complicated by cytopenias were reported. Sixteen percent patients presented a peripheral sensory neuropathy, 7% and 4% respectively grade 3–4 neutropenia and thrombocytopenia. Overall response was 84%, with 73% of complete remission. Median progression‐free survival was of 19.8 months (95% CI 13.1‐NR) and median overall survival was not reached with a median follow‐up of 31 months. We suggest that one‐day BV‐bendamustine (120 mg/m2) ever 21 days is a safe and feasible treatment for R/R HL especially for elderly patients.

01 Dec 2024·Journal of Cardiology Cases

Enhancement to effusion: Breast implant-associated anaplastic large cell lymphoma

Article

Author: Reddy, Neha K ; Mohammad, Khan O ; Patel, Akash P ; Ali, Syed H

This case is a rare presentation of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), where malignant pericardial effusion (MPE) served as the primary manifestation. A 58-year-old woman, post-breast implant removal, presented with pleuritic chest pain, fever, and chills. Clinical evaluation revealed jugular venous distention, muffled heart sounds, and hemodynamic instability. Echocardiogram with Doppler confirmed large pericardial effusion with tamponade physiology. Following a multidisciplinary discussion, a diagnostic and therapeutic pericardiocentesis was performed, resulting in immediate symptomatic relief.Cytology studies of the pericardial fluid revealed CD30+, ALK-ALCL, confirming BIA-ALCL. Prompt initiation of brentuximab-cyclophosphamide, doxorubicin, and prednisolone therapy ensued. This case underscores the rarity of MPE as an initial presentation of BIA-ALCL and highlights the significance of early recognition and consideration of rare lymphomas in patients with breast implants.Learning objectiveRecognize the importance of considering breast implant-associated anaplastic large cell lymphoma in the differential diagnoses of malignant pericardial effusion.

01 Oct 2024·Clinical and Translational Allergy

Retrospective analysis of rapid drug desensitization with biologic agents: A single center experience

Article

Author: Bavbek, Sevim ; Bayrak Durmaz, Makbule Seda ; Unutmaz Erkaya, Döne Gülçin ; Görgülü Akın, Begüm

AbstractBackgroundFollowing the increased use of biological agents, a subset of patients experiences hypersensitivity reaction (HSR). We reported our experience with rapid drug desensitization (RDD) to nine biologics (rituximab, infliximab, cetuximab, trastuzumab, pertuzumab, nivolumab, brentuximab, tocilizumab and filgrastim) and identified risk factors for breakthrough reactions (BTRs).MethodThis was a retrospective review (2013–2022) of patients with immediate HSRs to biological agents. Initial HSRs were classified as grade 1, 2, or 3 in their severity. Skin prick tests (SPT)/intradermal tests (IDT) were performed using implicated agents. The phenotypes of HSRs were defined as Type I, cytokine‐release syndrome (CRS), mixed reactions (cytokine‐release + type I) based on history, clinical presentations and skin tests with implicated biologicals. A 12‐step RDD protocol was used.ResultsThe study comprised 45 patients (F/M: 31/14, median age: 55 (range: 20–69)). Majority of the patients reacted at the first infusion (n: 29/45, 64.4%). The majority of initial HSRs were grade 3 (n: 24/45, 53.3%) and grade 2 (n: 21/45, 46.6%); none were grade 1. Initial reactions were presented as type I (n: 20/45, 44.4%), CRS (n: 12/45, 26.6%) and mixed (n: 13/45, 28.8%). A total of 258 RDDs were performed and 98.4% of them were completed successfully. BTRs occurred in 36/258 (13.9%) infusions of RDDs. There was no significant association between the BTRs and age, drug cycle, SPT and IDT positivity, gender, comorbidities, or atopy.ConclusionIn our experience, 98.4% of 258 RDDs to biologics were successfully completed; RDD was safe and effective for our population.

100 Deals associated with brentuximab

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EADV2023	Not Applicable	Sezary Syndrome CD30+	-	Brentuximab	shtgnslzeg(evijpwgphf) = jzfpgrbtzv rsxbfqsrsk (jibvcxwofw ) View more	Positive	11 Oct 2023
EHA2020	Not Applicable	Refractory Classic Hodgkin Lymphoma	-	Nivolumab and bendamustine	(yhrnwykkqz) = In the group 1 AE during treatment were observed in 94% of patients (severe AE - in 21%). In the group 2 AE were observed in 65% of patients (severe AE - in 4%). In the group 3 AE were observed in 68% of patients (severe AE - in 14%). In the group 4 AE were observed in 73% of patients (severe AE - in 27%). All cases of immune related AE resolved completely after treatment with glucocorticoids. jxqhuvdibr (lebqvlmlat )	Positive	14 May 2020
				Nivolumab and vinblastine
P2.6-015 (AAN2019)	Not Applicable	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Maintenance CD30+	-	Brentuximab	oxzkydwdiq(yduetzbcrk) = mvochknysr xinihzhyyn (tyryikyyhi ) View more	-	09 Apr 2019
ICML2017	Not Applicable	Refractory Hodgkin Lymphoma	32	Standard dose bendamustine (90 mg/sqm) + DHAP	izdnzvbtkj(pmhwmlzxvl) = cytomegalovirus (CMV) reactivation in 2 patients (18%), treated successfully with valganciclovir miinbgpsmk (wabjitnjcp ) View more	Positive	07 Jun 2017
				Brentuximab single agent 1.8 mg/kg

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

brentuximab

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation